DexCom, Inc. (DXCM) Price History:-8.75%(TTM)
The price cagr for DexCom, Inc. (DXCM) is -8.75% over the latest trailing 12-month period. The comparable SPY value is +22.92%. Year-to-date price return is +17.51%. Price CAGR uses adjusted close price history and excludes dividends.
Current Price
$78.19
+$1.57 (+2.05%)
Previous Close: $76.62
Today's Trading
- Open
- $77.48
- Day High
- $78.82
- Day Low
- $76.50
- Volume
- 4.76M
- Avg Volume
- N/A
52-Week Position
67%
of the 52-week price range
- From 52-week high
- -13.10%
- From 52-week low
- +44.50%
52-Week Price Range
52-Week Low
$54.11
Nov 10, 2025
Current Price
$78.19
67% of range
52-Week High
$89.98
Jul 28, 2025
Price Returns by Period
1 Day
+2.05%
7 Days
+6.45%
30 Days
+29.01%
YTD
+17.51%
1 Year
-8.74%
vs 52W High
-13.10%
DXCM Price Chart
Long-Term Performance (CAGR)
Price CAGR (3Y)
-14.32%
Price CAGR (5Y)
-4.32%
Total Return CAGR (3Y)
-14.32%
Total Return CAGR (5Y)
-4.32%
CAGR (Compound Annual Growth Rate) shows the annualized return over the specified period. Total Return includes dividends reinvested.
Key Price Statistics
| Current Price | $78.19 |
| Previous Close | $76.62 |
| Day Range | $76.50 - $78.82 |
| 52-Week Range | $54.11 - $89.98 |
| Volume | 4.76M |
| Average Volume | N/A |
| Market Cap | $30.17B |
| % from 52W High | -13.10% |
Related Metrics
About DexCom, Inc.
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Jacob Steven Leach